New Non-Nuceleotide Reverse Transcriptase Inhibitors for Drug Resistant HIV Strains
用于耐药 HIV 菌株的新型非核苷酸逆转录酶抑制剂
基本信息
- 批准号:10452754
- 负责人:
- 金额:$ 50.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-16 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAffinityAmino AcidsAnti-Retroviral AgentsAntiviral AgentsBindingBiological AssayBiological TestingChemicalsClinical Drug DevelopmentClinical TreatmentComputer AssistedComputer ModelsCoupledCrystallizationDockingDrug DesignDrug KineticsDrug TargetingDrug resistanceEffectivenessFutureGoalsHIVHIV drug resistanceHIV resistanceHIV-1HIV-1 drug resistanceHandIn VitroInfectionLigandsMethodologyModernizationModificationMulti-Drug ResistanceMutateMutationNNRTI-resistanceOutcomePatientsPharmaceutical ChemistryPharmaceutical PreparationsPharmacologyPharmacology StudyPlayPositioning AttributePreclinical Drug DevelopmentPropertyResearchResistanceResistance developmentResistance profileReverse Transcriptase InhibitorsRoleStructureSystemTechniquesTestingVariantViralVirusWorkantiretroviral therapybasechemical synthesisdesigndrug candidatedrug developmentdrug discoverydrug resistant virusdrug structurefitnessimprovedindexinglead optimizationmeetingsmolecular modelingmouse modelmutantnon-nucleoside reverse transcriptase inhibitorsresistance mutationscreeningsuccess
项目摘要
Abstract
Antiretroviral therapy (ART) for HIV/AIDS is effective in the clinical treatment of HIV-1 infections. Non-nucleoside
reverse transcriptase inhibitors (NNRTIs) are a class of anti-retrovirals playing a major role in the success of
ART. However, the emergence of drug resistant viruses has limited the usefulness of the NNRTIs in many
patients. Thus, new NNRTIs are needed to overcome current NNRTI resistant HIV strains. The goal of this study
is to identify new NNRTIs effective for drug resistant viruses. We have previously discovered two classes of
NNRTIs, diarylanilines (DAANs) and diarylpyridinamines (DAPAs), which are structurally different from the
approved diarylpyrimidine (DAPY)-type drugs etravirine and rilpivirine. Each of the chemical classes can fully
overcome some prevalent NNRTI resistant mutations. However, none of them was effective for all the prevalent
NNRTI resistant HIV-1 variants. To fully overcome the NNRTI resistance, we have identified the key structural
features from each of the chemical classes that are required for effectiveness against drug resistant viruses. We
hypothesize that a compound with structural features effective for drug resistant viruses can be synthesized and
will be effective for viruses resistant to current NNRTIs. To test our hypothesis and to accomplish our goal, we
propose to carry out the following two Specific Aims. Aim 1 is to design and synthesize new diarylaniline (DAAN)
and diarylpyridinamine (DAPA) derivatives to overcome HIV-1 variants resistant to NNRTIs. This aim will be
achieved by designing new NNRTIs that include favorable structural features for overcoming drug resistance
selected from DAANs/DAPAs. Aim 2 is to establish the pharmacological profiles of the new NNRTIs effective
against drug resistant HIV-1. The pharmacological study is aimed at establishing basic/initial pharmacological
profiles to pave the way for future more comprehensive drug-target interaction studies and clinical drug
development. Achieving this aim will provide the essential information to advance the compounds for further
preclinical drug development to mitigate NNRTI resistance. Our chemical synthesis will be supported by
conventional medicinal chemistry and modern molecular modeling. The lead optimization will be guided by well-
established primary and secondary biological testing against wild-type and NNRTI resistant virus, respectively.
The research team is positioned uniquely to conduct this endeavor based on over two decades of anti-HIV
research. With confirmed promising leads already on-hand, coupled with the availability of established bioassay
systems, we feel confident that we can discover and develop new NNRTIs to overcome the prevalent NNRTI
resistant viruses.
摘要
HIV/AIDS的抗逆转录病毒疗法(ART)在临床治疗HIV-1感染方面是有效的。非核苷
逆转录酶抑制物(NNRTI)是一类抗逆转录病毒药物,在抗逆转录病毒治疗的成功中起着重要作用
艺术。然而,抗药性病毒的出现限制了NNRTI在许多情况下的用途
病人。因此,需要新的NNRTI来克服目前对NNRTI耐药的艾滋病毒株。这项研究的目的是
是确定对耐药病毒有效的新的NNRTI。我们之前已经发现了两类
NNRTIs、二芳基苯胺(DAANs)和二芳基吡二胺(DAPAs),它们在结构上不同于
批准的二芳基嘧啶(DAPY)类药物依特拉韦林和利培韦林。每一节化学课都可以完全
克服一些流行的NNRTI耐药突变。然而,没有一种方法对所有流行的
耐NNRTI的HIV-1变种。为了完全克服NNRTI的阻力,我们已经确定了关键的结构性
有效对抗抗药性病毒所需的每一种化学类别的特征。我们
假设可以合成具有对抗药性病毒有效的结构特征的化合物,并且
将对对当前NNRTI具有耐药性的病毒有效。为了检验我们的假设并实现我们的目标,我们
建议实现以下两个具体目标。目标1设计和合成新的二芳基苯胺(DAAN)
和二芳基吡啶胺(DAPA)衍生物,以克服艾滋病毒-1变种对NNRTIs的抗药性。这一目标将是
通过设计新的NNRTI实现,该NNRTI包括克服耐药性的有利结构特征
从DAAN/DAPAS中选择。目标2是建立有效的新NNRTI的药理学概况
对抗抗药性HIV-1。药理学研究的目的是建立基础/初始药理学
为未来更全面的药物-靶点相互作用研究和临床药物铺平道路
发展。实现这一目标将为进一步发展化合物提供必要的信息
临床前药物开发以减轻NNRTI耐药性。我们的化学合成将由
传统药物化学和现代分子建模。领先的优化将由Well-Well指导
分别建立了对野生型和NNRTI耐药病毒的初级和二级生物学测试。
基于二十多年的抗艾滋病毒经验,该研究团队处于独特的地位来进行这项工作
研究。已经证实有希望的线索,再加上已建立的生物检测的可用性
我们相信,我们能够发现和开发新的NNRTI,以克服流行的NNRTI
抗药性病毒。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chin-Ho Chen其他文献
Chin-Ho Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chin-Ho Chen', 18)}}的其他基金
New Non-Nuceleotide Reverse Transcriptase Inhibitors for Drug Resistant HIV Strains
用于耐药 HIV 菌株的新型非核苷酸逆转录酶抑制剂
- 批准号:
10337386 - 财政年份:2021
- 资助金额:
$ 50.92万 - 项目类别:
New Non-Nuceleotide Reverse Transcriptase Inhibitors for Drug Resistant HIV Strains
用于耐药 HIV 菌株的新型非核苷酸逆转录酶抑制剂
- 批准号:
10653999 - 财政年份:2021
- 资助金额:
$ 50.92万 - 项目类别:
Aloperine derivatives as novel anti-influenza agents
作为新型抗流感药物的阿哌林衍生物
- 批准号:
9891004 - 财政年份:2019
- 资助金额:
$ 50.92万 - 项目类别:
Small Molecule HIV-1 Entry Inhibitor with Novel Mechanisms of Action
具有新颖作用机制的小分子 HIV-1 进入抑制剂
- 批准号:
9884724 - 财政年份:2018
- 资助金额:
$ 50.92万 - 项目类别:
Quinolizidines as Novel HIV-1 Entry Inhibitors
喹啉齐啶作为新型 HIV-1 进入抑制剂
- 批准号:
9322052 - 财政年份:2016
- 资助金额:
$ 50.92万 - 项目类别:
Intervening with Latent HIV-1 Infection using Gnidimacrin
使用 Gnidimacrin 干预潜伏性 HIV-1 感染
- 批准号:
8658778 - 财政年份:2014
- 资助金额:
$ 50.92万 - 项目类别:
Intervening with Latent HIV-1 Infection using Gnidimacrin
使用 Gnidimacrin 干预潜伏性 HIV-1 感染
- 批准号:
8828549 - 财政年份:2014
- 资助金额:
$ 50.92万 - 项目类别:
Small Molecules that Regulate Proteasome Activity
调节蛋白酶体活性的小分子
- 批准号:
7939288 - 财政年份:2009
- 资助金额:
$ 50.92万 - 项目类别:
Small Molecules that Regulate Proteasome Activity
调节蛋白酶体活性的小分子
- 批准号:
7748967 - 财政年份:2009
- 资助金额:
$ 50.92万 - 项目类别:
Small Molecules that Regulate Proteasome Activity
调节蛋白酶体活性的小分子
- 批准号:
8204613 - 财政年份:2009
- 资助金额:
$ 50.92万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 50.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 50.92万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 50.92万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 50.92万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 50.92万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 50.92万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 50.92万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 50.92万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 50.92万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 50.92万 - 项目类别:
Continuing Grant